(UroToday.com) In the Controversy session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Karim Fizazi and Dr. Ronald De Wit debated the question of whether enhanced androgen signaling inhibition should be the treatment of choice for treatment of metastatic castration sensitive prostate cancer (mCSPC) rather than docetaxel. Presenting second, Dr. de Wit supported the use of docetaxel.